The integration of generative AI in the Life Sciences: towards predictive biology

The meeting of molecular biology and advanced artificial intelligence is marking a historic turning point for medicine. This is not simply about more powerful tools, but about a real paradigm shift: we are moving from a science that observes and describes life to one that can predict it — and increasingly, design it.

For decades, biomedical research relied on a slow and costly trial-and-error approach. Developing a new drug could take more than ten years and cost over $2 billion, with a high failure rate along the way.

Today, that model is rapidly changing. Thanks to advances in deep learning, problems long considered unsolvable—such as protein folding, a crucial step to understand how biological molecules function—have been addressed. This has opened the door to a new possibility: designing completely new molecules on a computer with precision down to the atomic level.

In this scenario, biology is increasingly becoming a data science. Value no longer resides solely in the physical synthesis of a molecule, but in the ability to predict its structure and behavior through computational models. In other words, innovation is shifting from the lab to the algorithm.

The consequences are profound. Discovery timelines shrink drastically—from years to a few months—and it becomes possible from the outset to optimize crucial parameters like efficacy and safety, reducing the risk of side effects before clinical testing.

This transformation also has a significant economic impact. The traditional model of large pharmaceutical companies, based on massive investments and long development cycles, is being challenged. Small, lean, highly specialized startups can now compete thanks to access to advanced computational resources.

A kind of “democratization” of scientific research thus emerges: as technological barriers fall, the number of actors able to innovate increases. This could lead to a revision of patent systems and drug pricing models, traditionally linked to the rarity and cost of discovery.

At the same time, healthcare systems will need to adapt. The medicine of the future will be less standardized and increasingly personalized: treatments designed for the individual patient based on their genetic and biological profile.

In this new context, the researcher’s role also changes. The bioinformatician—able to integrate biological expertise and data analysis—is becoming increasingly central. Artificial intelligence does not replace the scientist, but redefines their work: from direct data production to the supervision, interpretation, and validation of results.

The ultimate goal is ambitious: to enable personalized medicine at scale, where therapies are no longer standard but adapted in real time to each individual’s characteristics.

However, this acceleration also raises crucial questions. How can we validate drugs designed by complex algorithms that are often hard to interpret? How can we ensure patient safety and protect highly sensitive biological data?

The challenge of the coming years will be to find a balance between innovation and regulation: building a system capable of supporting the speed of progress without sacrificing safety, transparency, and equity in access to care.

Because the real goal is not only to make medicine more powerful, but also fairer and more accessible.

Editorial written by professor Antonio Giordano for “Medicina gli Highlights” - column published in Il Mattino.